BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

GlaxoSmithKline (GSK): We Conducted Paxil Clinical Trial Program Appropriately


12/7/2012 8:52:23 AM

Pharmaceutical giant GlaxoSmithKline says it conducted its clinical trial program for the anti-depressant drug Paxil appropriately in marketing the medicine for use by women of childbearing age. The statement comes after a B.C. Supreme Court judge certified a class-action lawsuit launched by a British Columbia mother whose daughter was born with a hole in her heart. Lawyers allege the drug caused birth defects when taken during pregnancy, and say the company didn't properly warn doctors about the risks. In a statement, spokeswoman Michelle Smolenaars Hunter says the company acted appropriately in its clinical trials, marketing, safety monitoring and updated pregnancy information as new information became available. Faith Gibson's daughter Meah Bartram was born just two weeks before the company warned doctors that taking the drug during pregnancy could increase the chance of cardiovascular defects. One of her lawyers, David Klein, argues the company ought to have know the risks before then, and is pointing to small-scale studies and studies on similar products that were already available to the scientific community. But Smolenaars Hunter says the company acted responsibly.

Read at Vancouver Sun

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->